Hubei Cancer Hospital ( Site 0514)

Wuhan, Hubei 430079

0 studies enrolling now · 1 studies all time

What they study most

Esophageal Adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC)

Studies at this site

• Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) — Completed